Ir para o conteúdo principal

Merck & Company (NYSE: MRK) — Perfil da empresa, notícias e dados financeiros

Logo de Merck & Company
MRK Merck & Company
A people working in a pharmaceutical factory
Perfil da empresa

Merck & Company

Merck & Company is a global healthcare enterprise that discovers, develops, manufactures, and markets biopharmaceutical prescription medicines, vaccines, biological therapies, and animal health products. The company operates through two main business segments: Pharmaceutical and Animal Health. Its pharmaceutical portfolio includes treatments across oncology, infectious diseases, cardiometabolic disorders, immunology, neuroscience, and respiratory conditions. Additionally, the organization develops and supplies vaccines for pediatric, adolescent, and adult populations, alongside veterinary medicines and health management products for livestock and companion animals worldwide.

Resumo

Public USParticipação acionária
1891Ano de fundação
~75,000Funcionários
Rahway, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States
Japan

Produtos e/ou serviços de Merck & Company

  • Oncology Therapeutics: Monoclonal antibodies and immunotherapies designed for cancer treatments, targeting programmatic cell death proteins across multiple solid tumor types, hematologic malignancies, and early-stage disease settings across international markets.
  • Vaccines Portfolio: Human vaccines covering pediatric, adolescent, and adult immunizations for human papillomavirus, pneumococcal disease, rotavirus, measles, mumps, rubella, and varicella distributed to global health programs and clinical networks.
  • Cardiometabolic and Respiratory Medicines: Pharmaceutical treatments targeting pulmonary arterial hypertension, type 2 diabetes, hypercholesterolemia, and chronic heart failure administered through oral formulations and specialized therapies across healthcare systems worldwide.
  • Infectious Disease Treatments: Antiviral and antibacterial formulations providing therapeutic interventions for human immunodeficiency virus infections, severe fungal infections, cytomegalovirus in transplant recipients, and hospital-acquired bacterial infections.
  • Immunology and Neuroscience Products: Targeted pharmaceutical biologicals and small molecule drugs engineered to manage autoimmune conditions, chronic inflammatory disorders, neurodegenerative conditions, and central nervous system disorders worldwide.
  • Animal Health Solutions: Veterinary pharmaceuticals, biological products, vaccines, and digital livestock intelligence services for livestock, poultry, aquaculture, and companion animals distributed to veterinarians, producers, and pet owners globally.

equipe executiva do Merck & Company

  • Robert M. DavisChairman, President & CEO
  • Caroline A. LitchfieldExecutive VP & CFO
  • Jennifer L. ZacharyExecutive VP & General Counsel
  • Dean Y. LiExecutive VP & President of Merck Research Laboratories
  • Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller
  • Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
  • Peter DannenbaumVice President of Investor Relations
  • Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications
  • Betty D. LarsonExecutive VP & Chief Human Resources Officer
  • Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health

Comunicados recentes

O que a Merck & Company (MRK) comunicou ao mercado, do mais recente para o mais antigo.

  1. 4 | Merck & Co., Inc.

Histórico de dividendos

Dividendos por ação pagos pela Merck & Company, por ano fiscal.

Dividendos por ação da Merck & Company por ano fiscal
Ano fiscalIntermediárioFinalEspecialTotal
FY2026(até o momento)———$2.5500
FY2025———$3.2800
FY2024———$3.1200
FY2023———$2.9600
FY2022———$2.8000

Principais indicadores financeiros

Resultados divulgados pela Merck & Company, em USD.

Cap. de mercado
364,3 bi
Receita (TTM)
67,4 bi
P/L
147.8
LPA (diluído, TTM)
1.0
Dividend yield
2.3%
Margem de lucro
3.6%
Receita e lucro anuais da Merck & Company
Fim do ano fiscalReceitaResultado operacionalLucro líquido
64,9 bi23,5 bi18,3 bi
64,2 bi20,2 bi17,1 bi
60,1 bi3 bi365 mi
59,3 bi18,3 bi14,5 bi